Lung Therapeuticsbased In Austintexasis A Clinical Stage Biopharmaceutical Company Founded In 2013The Company Specializes In Developing Therapies For Rare Lung Disordersparticularly Those Related To Fibrosisrecently Acquired By Aileron Therapeutics In October 2023Lung Therapeutics Is Now Part Of A Broader Initiative Targeting Orphan Drug Indications For Lung Diseases The Company Is Advancing Several Clinical Stage Drug Candidatesincluding Lti 03Which Targets Idiopathic Pulmonary Fibrosisipf And Lti 01Aimed At Treating Loculated Pleural Effusionlpe Lung Therapeutics Holds Nine Patentsincluding One For Modified Peptide Fragments Of The Cav 1 Proteinwhich Are Designed To Address Fibrosis And Inflammationwith A Focus On Translating Extensive Research Into Effective Treatmentslung Therapeutics Is Dedicated To Serving Underserved Patient Populations Affected By Rare Lung Conditions
No conferences found for this company.
| Company Name | Lung Therapeutics Inc |
| Country |
United States
|
| Address | N/A |
| Telephone | N/A |
| N/A |
